Background & Aims Safety is a key consideration when choosing advanced therapies
(biologic agents and oral small-molecule inhibitors/modulators) in patients with inflammatory …

The availability of biologic therapies in inflammatory bowel disease (IBD) is increasing
significantly. This represents more options to treat patients, but also more difficulties in …

Abstract Background and Aims Many observational studies on the use of vedolizumab [VDZ]
in patients with Crohn's disease [CD] and ulcerative colitis [UC] have been published in the …

Abstract Background and Aims This study compares the effectiveness of different biologic
therapies and sequences in patients with inflammatory bowel disease [IBD] using real-world …

Background The expanding options in advanced therapies for ulcerative colitis (UC) and
Crohn's disease (CD) present challenges in treatment selection. Persistence analysis …

Purpose To analyze treatment persistence and treatment outcomes of vedolizumab as first-
line biological treatment in Crohn's disease (CD) and ulcerative colitis (UC) patients in a …

Objective: Adalimumab (ADA) is an effective treatment for inflammatory bowel disease (IBD),
both ulcerative colitis (UC) and Crohn's disease (CD). The equal effect between the original …

Abstract Background and Aims Etrasimod is an oral, once daily, selective sphingosine 1-
phosphate [S1P] 1, 4, 5 receptor modulator for the treatment of moderately to severely active …

Objectives: We aimed to assess the risk of serious infection in inflammatory bowel disease
(IBD) patients treated with vedolizumab, compared to those treated with anti-tumor necrosis …

Wie wichtig es ist, auch schon bei jungen Patienten frühzeitig mit einer First-line-
Biologikatherapie zu beginnen, demonstrierte Blumenstein anhand eines Patientenfalles …